RLAY Relay Therapeutics Inc
Company Analysis
Latest News
🔴 Relay Therapeutics falls 4.0% — Biotech Sector Declines Amid Broad Market Rotation
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...
🔴 Relay Therapeutics is trading 7.83% down in pre-market — no clear company-specific explanation found
Relay Therapeutics is trading at $16.00, down 7.83% in pre-market, with no clear company-specific announcement identified to explain the decline. - The shares...
🔴 Relay Therapeutics is trading 4.23% down in pre-market — catalyst unclear
Relay Therapeutics is trading at $17.22, down 4.23% in pre-market; the reason for the decline remains unclear. - Searches found no clear company-specific...
🟢 Relay Therapeutics rises 4.0% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Relay Therapeutics is trading 4.1% down with no confirmed company-specific catalyst
Relay Therapeutics is trading 4.1% down at $17.21, with no confirmed company-specific announcement explaining the October 8 decline. - Available coverage...
🔴 Relay Therapeutics is trading 4% down with no confirmed company-specific catalyst
Relay Therapeutics is trading 4.00% down at $17.99, with no clear company-specific catalyst identified. - No clear October 7 company announcement explaining...
🔴 Relay Therapeutics is trading 4.7% down
Relay Therapeutics is trading 4.7% down at $18.48; the precise cause of the decline remains unclear. - No clear company-specific announcement or catalyst...
🔴 Relay Therapeutics is trading 7% down in pre-market amid possible biotech-sector weakness
Relay Therapeutics is trading at $17.20, down 6.98%, with biotech-sector weakness possibly contributing to the pre-market decline. - It closed at $18.49 on...
🟢 Relay Therapeutics is trading 4.3% up — catalyst unconfirmed
Relay Therapeutics is trading 4.32% higher at $18.83 on October 1, 2026, with the move’s specific driver unconfirmed. - Available search results show no clear...
🟢 Relay Therapeutics is trading 4.32% up
Relay Therapeutics is trading at $18.45, up +4.32%, with no clear company announcement or event dated September 29 explaining the gain. - Recent Phase...
Relay Therapeutics Triggers Milestone Payments, Following FDA Approval of Lyrfigtu
The U.S. Food and Drug Administration approved Lyrfigtu (lirafugratinib) for adults with previously treated bile duct cancer. This approval targets patients...
🔴 Relay Therapeutics is trading 10.72% down today amid broader risk-off trading
Relay Therapeutics is trading 10.72% down now at $17.27, with the decline appearing primarily linked to broader risk-off trading; no clear company-specific...
🔴 Relay Therapeutics is trading 4.03% down today; catalyst remains unclear
Relay Therapeutics is trading 4.03% lower at $18.57, with no identified company-specific announcement explaining the September 23 decline. - The decline...
Relay Therapeutics' Cancer Drug, Originating from X-Chem's Discovery Platform, Reaches Phase 3 Trial
X-Chem earned a milestone payment from Relay Therapeutics (RLAY). This followed Relay's initiation of a Phase 3 clinical trial for zovegalisib (RLY-2608). The...
🟢 Relay Therapeutics is trading 4.3% up today — no clear catalyst identified
Relay Therapeutics is trading 4.3% up at $18.98, with no clear company-specific or macro-driven catalyst identified for the September 22, 2026 move. - Recent...
🔴 Relay Therapeutics is trading 4% down today
Relay Therapeutics is trading 4.03% down now at $18.08, with no clear company-specific catalyst emerging on September 21, 2026. - Recent coverage describes...
🟢 Relay Therapeutics rises 4.1% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
Relay Therapeutics Lands $19 Million Frazier Stake Amid Insider Selling
Frazier Life Sciences Management L.P. acquired 1,015,693 shares of Relay Therapeutics. The new position is valued at approximately $19 million according to a...
Relay Therapeutics Shareholder Sells $116.4 Million Stake After Stock Rally
SVF Pauling (Cayman) Ltd sold 6,000,000 shares of Relay Therapeutics common stock. The transaction occurred on August 25, 2026. The SoftBank Vision Fund...
🔴 Relay Therapeutics falls 4.0% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...